Free Trial
NASDAQ:PIRS

Pieris Pharmaceuticals Q4 2023 Earnings Report

Pieris Pharmaceuticals EPS Results

Actual EPS
-$4.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pieris Pharmaceuticals Revenue Results

Actual Revenue
$1.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pieris Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 29, 2024
Conference Call Time
8:00AM ET

Pieris Pharmaceuticals Earnings Headlines

Pieris Pharmaceuticals Inc
Palvella Therapeutics Inc (PVLA)
From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
One new option listing and one option delisting on December 16th
See More Pieris Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pieris Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pieris Pharmaceuticals and other key companies, straight to your email.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals (NASDAQ:PIRS), a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

View Pieris Pharmaceuticals Profile

More Earnings Resources from MarketBeat